Skip to main content
BNR
NASDAQ Industrial Applications And Services

Burning Rock Biotech Reports Q1 2026 Revenue Decline and Increased Net Loss

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$9.07
Mkt Cap
$95.401M
52W Low
$2.88
52W High
$41.72
52W Position info
215% above low
Off High info
78% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

BNR has more than doubled off its 52-week low of $2.88.

Summary

Burning Rock Biotech reported a substantial 18.9% year-over-year revenue decrease and an increased net loss for the first quarter of 2026, despite efforts to reduce operating expenses.


Key Events · Earnings and Guidance · BNR

  • Total Revenue Decreased

    Q1 2026 revenues were RMB107.9 million (US$15.6 million), an 18.9% decrease from RMB133.1 million in Q1 2025. This decline was observed across central laboratory (-15.3%), in-hospital (-8.5%), and pharma R&D services (-38.6%) segments.

  • Net Loss Increased

    The company reported a net loss of RMB17.5 million (US$2.5 million) for Q1 2026, compared to a net loss of RMB13.5 million in Q1 2025, indicating a worsening bottom line year-over-year.

  • Operating Expenses Reduced

    Operating expenses decreased by 14.0% year-over-year to RMB96.9 million (US$14.1 million), primarily driven by a 31.8% reduction in research and development expenses, reflecting cost control efforts.

  • Cash Position Update

    Cash, cash equivalents, and restricted cash stood at RMB448.7 million (US$65.1 million) as of March 31, 2026, a decrease from RMB478.4 million at the end of 2025.


Analysis · BNR · Industrial Applications And Services

Burning Rock Biotech reported a significant 18.9% year-over-year decrease in total revenues for Q1 2026, impacting all business segments. This revenue decline, coupled with an increase in net loss compared to the prior year, marks a reversal from the positive trend of loss reduction seen in previous quarters. While the company demonstrated cost control by reducing operating expenses, the worsening top-line and bottom-line performance is a material concern for investors.

How filings like this one have moved

In the 30 days to Nov 8, 2026, 46.9% of the 1569 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.35%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BNR was trading at $9.07 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $95.4M. The 52-week trading range was $2.88 to $41.72. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BNR - Latest Insights

BNR
Sep 10, 2026, 7:29 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $11.60
Real-time Price: $13.42 info
Change: +$1.82 (+16%) info
Market Cap: $134.949M info
BNR
Jul 02, 2026, 8:30 AM EDT
Filing Type: 4
Importance Score:
9
Price at Filing: $8.96
Real-time Price: $13.42 info
Change: +$4.46 (+50%) info
Market Cap: $134.949M info
BNR
Apr 28, 2026, 6:08 AM EDT
Filing Type: 20-F
Importance Score:
9
Price at Filing: $19.06
Real-time Price: $13.42 info
Change: -$5.64 (-30%) info
Market Cap: $134.949M info
BNR
Apr 02, 2026, 7:17 AM EDT
Filing Type: 4
Importance Score:
9
Price at Filing: $16.30
Real-time Price: $13.42 info
Change: -$2.88 (-18%) info
Market Cap: $134.949M info
BNR
Mar 12, 2026, 8:58 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $23.46
Real-time Price: $13.42 info
Change: -$10.04 (-43%) info
Market Cap: $134.949M info